

FASTEV

A SUPERIOR EXTRACELLULAR VESICLE ISOLATION METHOD FOR BIOMARKER DISCOVERY AND THERAPEUTICS

Personalized health care and medicine are expected to solve major economical problems by enabling improved screening and targeted treatment of diseases in future. Here, **extracellular vesicles (EVs)** offer a **recently appreciated** global source of **promising** biomarkers and novel therapies. *The bottle neck* in the exploitation of EVs is the laborious, expensive and slow manual work-requiring isolation of EVs which needs special expertise to produce pure EVs. We have developed a novel, simple, fast, scalable and cost-effective method for EV isolation, FastEV. **FastEV produces a pure EV preparation with versatile applicability in both biomarker studies and therapy.** We are currently planning further development of FastEV for multiple sample types and technological platforms.

Maija Puhka, PhD

RESEARCH SCIENTIST, HEAD AND COFOUNDER OF EV CORE FIMM, UNIVERSITY OF HELSINKI

Maija's experience in the EV field covers technical development of tools, handling, storage and biomarker discovery of biobank materials as well as set-up and running of the first academic EV Core service in the World.



Pia Siljander, Docent

GROUP LEADER, LECTURER, CHAIR AND FOUNDER OF EV CORE AT UNIVERSITY OF HELSINKI

Pia has a longstanding experience of EVs already from her PhD. Her research group's topics cover EVs from basic communication mechanisms to drug delivery and biomarker discovery. Pia is a founding member of the International Society of Extracellular vesicles and the MC for Finland in EU COST Action for EVs.



SPARK VALUE: We expect that SPARK will help us to improve the commercial maturity of FastEV by identifying the most promising customer segments, applications and commercialization strategies.